FDA Preference For Single-Dose Bioequivalence Studies Restated
Executive Summary
There are "very, very few cases" where "multiple-dose studies add anything different, a different insight," to single-dose bioequivalence studies, FDA Center for Drug Evaluation & Research Bioequivalence Division Director Dale Conner, PharmD, told FDA's Pharmaceutical Science Advisory Committee Oct. 22.